The Value of Measuring Lipoprotein(a) in Children

HomeCirculationVol. 147, No. 1The Value of Measuring Lipoprotein(a) in Children No AccessEditorialRequest AccessFull TextAboutView Full TextView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toNo AccessEditorialRequest AccessFull TextThe Value of Measuring Lipoprotein(a) in Children Michael Khoury, MD and Shoa L. Clarke, MD, PhD Michael KhouryMichael Khoury Correspondence to: Michael Khoury, MD, Pediatric Cardiology, Department of Pediatrics, Stollery Children’s Hospital, 8440-112th St NW, Edmonton, AB, Canada T6G 2B7. Email E-mail Address: [email protected] https://orcid.org/0000-0001-6112-6860 Department of Pediatrics, University of Alberta, Edmonton, Canada (M.K.). Search for more papers by this author and Shoa L. ClarkeShoa L. Clarke https://orcid.org/0000-0002-6592-1172 Department of Medicine, Division of Cardiovascular Medicine (S.L.C.), Stanford University School of Medicine, California. Department of Pediatrics, Division of Pediatric Cardiology (S.L.C.), Stanford University School of Medicine, California. Search for more papers by this author Originally published28 Dec 2022https://doi.org/10.1161/CIRCULATIONAHA.122.062592Circulation. 2023;147:32–34This article is a commentary on the followingLipoprotein(a) in Youth and Prediction of Major Cardiovascular Outcomes in AdulthoodFootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.For Sources of Funding and Disclosures, see page 34.Circulation is available at www.ahajournals.org/journal/circCorrespondence to: Michael Khoury, MD, Pediatric Cardiology, Department of Pediatrics, Stollery Children’s Hospital, 8440-112th St NW, Edmonton, AB, Canada T6G 2B7. Email [email protected]caReferences1. Raitakari OT, Juonala M, Kahonen M, Taittonen L, Laitinen T, Maki-Torkko N, Jarvisalo MJ, Uhari M, Jokinen E, Ronnemaa T, et al. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study.JAMA. 2003; 290:2277–2283. doi: 10.1001/jama.290.17.2277CrossrefMedlineGoogle Scholar2. Jacobs DR, Woo JG, Sinaiko AR, Daniels SR, Ikonen J, Juonala M, Kartiosuo N, Lehtimaki T, Magnussen CG, Viikari JSA, et al. Childhood cardiovascular risk factors and adult cardiovascular events.N Engl J Med. 2022; 386:1877–1888. doi: 10.1056/NEJMoa2109191CrossrefMedlineGoogle Scholar3. Berenson GS, Srinivasan SR, Bao W, Newman WP, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults: the Bogalusa Heart Study.N Engl J Med. 1998; 338:1650–1656. doi: 10.1056/NEJM199806043382302CrossrefMedlineGoogle Scholar4. Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, Lloyd-Jones DM, Marcovina SM, Yeang C, Koschinsky ML, et al; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; and Council on Peripheral Vascular Disease. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association.Arterioscler Thromb Vasc Biol. 2022; 42:e48–e60. doi: 10.1161/ATV.0000000000000147LinkGoogle Scholar5. O’Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, Im K, Lira Pineda A, Wasserman SM, Ceska R, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk.Circulation. 2019; 139:1483–1492. doi: 10.1161/CIRCULATIONAHA.118.037184LinkGoogle Scholar6. Raitakari OT, Kartiosuo N, Pahkala K, Hutri-Kahonen N, Bazzano LA, Chen W, Urbina EM, Jacobs DR, Sinaiko A, Steinberger J, et al. Lipoprotein(a) in youth and prediction of major cardiovascular outcomes in adulthood.Circulation. 2023; 147:23–31. doi: 10.1161/CIRCULATIONAHA.122.060667LinkGoogle Scholar7. Trinder M, Paruchuri K, Haidermota S, Bernardo R, Zekavat SM, Gilliland T, Januzzi J, Natarajan P. Repeat measures of lipoprotein(a) molar concentration and cardiovascular risk.J Am Coll Cardiol. 2022; 79:617–628. doi: 10.1016/j.jacc.2021.11.055CrossrefMedlineGoogle Scholar8. Spence JD, Koschinsky M. Mechanisms of lipoprotein(a) pathogenicity: prothrombotic, proatherosclerotic, or both?Arterioscler Thromb Vasc Biol. 2012; 32:1550–1551. doi: 10.1161/ATVBAHA.112.251306LinkGoogle Scholar9. Grebe MT, Schoene E, Schaefer CA, Boedeker RH, Kemkes-Matthes B, Voss R, Tillmanns HH. Elevated lipoprotein(a) does not promote early atherosclerotic changes of the carotid arteries in young, healthy adults.Atherosclerosis. 2007; 190:194–198. doi: 10.1016/j.atherosclerosis.2006.01.017CrossrefMedlineGoogle Scholar10. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: summary report.Pediatrics. 2011; 128(suppl 5):S213–S256. doi: 10.1542/peds.2009-2107CCrossrefMedlineGoogle Scholar11. Luirink IK, Wiegman A, Kusters DM, Hof MH, Groothoff JW, de Groot E, Kastelein JJP, Hutten BA. 20-Year follow-up of statins in children with familial hypercholesterolemia.N Engl J Med. 2019; 381:1547–1556. doi: 10.1056/NEJMoa1816454CrossrefMedlineGoogle Scholar12. de Ferranti SD, Steinberger J, Ameduri R, Baker A, Gooding H, Kelly AS, Mietus-Snyder M, Mitsnefes MM, Peterson AL, St-Pierre J, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association.Circulation. 2019; 139:e603–e634. doi: 10.1161/CIR.0000000000000618LinkGoogle Scholar13. Khoury M, Bigras JL, Cummings EA, Harris KC, Hegele RA, Henderson M, Morrison KM, St-Pierre J, Wong PD, McCrindle BW. The detection, evaluation, and management of dyslipidemia in children and adolescents: a Canadian Cardiovascular Society/Canadian Pediatric Cardiology Association clinical practice update.Can J Cardiol. 2022; 38:1168–1179. doi: 10.1016/j.cjca.2022.05.002CrossrefMedlineGoogle Scholar14. Ellis KL, Perez de Isla L, Alonso R, Fuentes F, Watts GF, Mata P. Value of measuring lipoprotein(a) during cascade testing for familial hypercholesterolemia.J Am Coll Cardiol. 2019; 73:1029–1039. doi: 10.1016/j.jacc.2018.12.037CrossrefMedlineGoogle Scholar15. Nissen SE, Wolski K, Cho L, Nicholls SJ, Kastelein J, Leitersdorf E, Landmesser U, Blaha M, Lincoff AM, Morishita R, et al. Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease.Open Heart. 2022; 9:e002060. doi: 10.1136/openhrt-2022-002060CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsRelated articlesLipoprotein(a) in Youth and Prediction of Major Cardiovascular Outcomes in AdulthoodOlli Raitakari, et al. Circulation. 2023;147:23-31 January 3, 2023Vol 147, Issue 1 Advertisement Article InformationMetrics © 2022 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.122.062592PMID: 36576957 Originally publishedDecember 28, 2022 Keywordslipoproteinchildrisk factorsEditorialsatherosclerosisPDF download Advertisement SubjectsCardiovascular DiseasePediatrics